# Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

> **NCT00603265** · PHASE2 · COMPLETED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 226 (actual)

## Conditions studied

- Peripheral Neuropathy
- Neuropathic Pain

## Interventions

- **DRUG:** ADL5859
- **DRUG:** Duloxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00603265
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2015-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00603265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00603265, "Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00603265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*